Faculty of Medicine

Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14

Browse

Settings

Author: search.filters.author.Belchishta, Anila

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Efficacy of Alendronate in Preventing Periprosthetic Bone Loss after Implantation of a Primary Hip Endoprosthesis
    (Scientific Foundation SPIROSKI, 2022-07)
    Shabani, Ilir
    ;
    ;
    ;
    ;
    BACKGROUND: Total hip arthroplasty (THA) is now the gold standard for the surgical treatment of coxarthrosis. The appearance of bone loss after implantation of the hip endoprosthesis over time reduces the primary stability of the implant and leads to progressive loosening of the implant or periprosthetic fracture, which are considered to be the most common causes of hip revision. AIM: The aim of this study is to evaluate the value of alendronate application in reducing periprosthetic osteolysis reduction after implantation of total cementless hip endoprosthesis. METHODS: The study analyzed 50 patients operated on with implantation of a cementless THA. The first group of 25 patients received oral alendronate, calcium, and Vitamin D3 postoperatively. The second group of 25 patients was examined and followed postoperatively without any therapy. Patients were examined by RTG and dual energy X-ray absorption (DXA) methods at 6, 12, and 18 months. RESULTS: The study showed a difference in the values of bone mineral density and bone mineral content in the interval of 6,12, and 18 months, using the DXA method. CONCLUSION: Alendronate therapy after total hip implantation reduces periprosthetic bone loss, maintains bone mineralization, and strengthens the implant.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Influence of alendronate therapy on the results of densitometric examination after implantation of total hip endoprosthesis
    (Scientific Foundation SPIROSKI, 2021-06-20)
    Shabani, Ilir
    ;
    ;
    Velkovski, Vilijam
    ;
    ;
    The development of aloarthroplasty of the hip is continuously rising. After implantation of a total cement-free hip endoprosthesis, often there is a periprosthetic femoral bone loss. Alendronate has been shown to be a potent inhibitor of bone resorption activity; it inhibits osteoclastic bone resorption, increases bone mass, and plays a significant role in post-implantation stabilization of the femur. The aim of this study was to determine the effect of alendronate on osteointegration of hip endoprosthesis.Material and methods: The study analyzed 10 patients operated on with implantation of a total cement-free hip endoprosthesis (THP). The included patients were examined by a radiographic method at 6 and 12 months and DXA method at 6 and 12 months. Results: The study showed differences in the values of bone mineral density and bone mineral content in the interval between 6 and 12 months in patients undergoing THP, and hence we can conclude that alendronate therapy after THP implantation reduced periprosthetic loss of bone mass and implant stiffening. Alendronate is a proven inhibitor of periprosthetic bone loss that occurs after prirmary impantation of a total cement-free hip endoprosthesis.